Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy

Bone Marrow Transplant. 1989 Jan;4(1):113-4.


A patient with acute myeloblastic leukemia received high-dose busulfan (1 mg/kg by mouth every 6 h for 4 days) as myelo-ablative therapy for autologous bone marrow transplantation. Rapid entry of busulfan into the cerebrospinal fluid (CSF) was observed. Plasma and CSF concentrations of busulfan were comparable during the 4 days of treatment. The elimination half-lives of busulfan in plasma and CSF were 2.6 h and 2.8 h respectively during the first 12 h after the last dose.

MeSH terms

  • Bone Marrow Transplantation
  • Busulfan / administration & dosage
  • Busulfan / blood
  • Busulfan / cerebrospinal fluid
  • Busulfan / pharmacokinetics*
  • Half-Life
  • Humans
  • Leukemia, Myeloid, Acute / blood
  • Leukemia, Myeloid, Acute / cerebrospinal fluid
  • Leukemia, Myeloid, Acute / surgery
  • Male
  • Middle Aged
  • Neoplasms, Multiple Primary
  • Preoperative Care


  • Busulfan